BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Viridian Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 09:22 am Sale |
2023-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-2,302,094 (Position Closed) |
Filing |
| 2023-02-14 11:43 am Purchase |
2022-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
BIOTECHNOLOGY VALUE FUND L P | 2,302,094 5.600% |
99,779 (+4.53%) |
Filing |
| 2022-02-14 1:51 pm Purchase |
2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
BIOTECHNOLOGY VALUE FUND L P | 2,202,315 9.990% |
2,202,315 (New Position) |
Filing |